What's new in neurofibromatosis? Proceedings from the 2009 NF conference: New frontiers

American Journal of Medical Genetics, Part A

Volumn 152, Issue 2, 2010, Pages 269-283

  Kissil, Joseph L ^a   Blakeley, Jaishri O ^b   Ferner, Rosalie E ^c   Huson, Susan M ^d   Kalamarides, Michel ^e,f   Mautner, Victor Felix ^g   McCormick, Frank ^h   Morrison, Helen ⁱ   Packer, Roger ^j   Ramesh, Vijaya ^k   Ratner, Nancy ^l   Rauen, Katherine A ^h   Stevenson, David A ^m   Hunter Schaedle, Kim ⁿ   North, Kathryn ^o  

^a WISTAR INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e BEAUJON HOSPITAL   (France)

^f INSERM   (France)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ FRITZ LIPMANN INSTITUTE   (Germany)

^j CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ Children's Tumor Foundation   (United States)

^o UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Bone dysplasia; Learning disabilities; Neurofibromatosis type 1; Neurofibromatosis type 2; NF1; NF2; Ras MAPK; Schwannomatosis; Tumor suppressor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; DOXYCYCLINE; EVEROLIMUS; IMATINIB; INTERFERON; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEVINOLIN; NX 101; PIRFENIDONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PTC 299; RANIBIZUMAB; RAPAMYCIN; SIMVASTATIN; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VORINOSTAT;

BONE DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DERMAL NEUROFIBROMA; DISEASE COURSE; DRUG SCREENING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INJECTION SITE DISCOMFORT; LEARNING DISORDER; MENINGIOMA; MISSENSE MUTATION; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; NEUROFIBROMATOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PRURITUS; TREATMENT RESPONSE; VASCULAR DISEASE;

ANIMALS; CHILD; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; MICE; NERVOUS SYSTEM NEOPLASMS; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 75449091573     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.33189     Document Type: Conference Paper

References (29)

1. Boyd C, Smith MJ, Kluwe L, Balogh A, MacCollin M, Plotkin SR. 2008. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 74:358-366.
2. Boyd KP, Korf BR, Theos A. 2009. Neurofibromatosis type 1. J Am Acad Dermatol 61:1-14.
3. Brems H, Chmara M,SahbatouM, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E. 2007. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120-1126.
4. Denayer E, Ahmed T, Brems H, Van Woerden G, Borgesisu NZ, Callaerts-Vegh Z, Yoshimura A, Hartmann D, Elgersma Y, D'Hooge R, Legius E, Balschun D. 2008. Spred1 is required for synaptic plasticity and hippocampus-dependent learning. J Neurosci 28:14443-14449.
5. Eerola I, Boon LM, Mulliken JB, Burrows PE, Dompmartin A, Watanabe S, Vanwijck R, Vikkula M. 2003. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 73:1240-1249.
6. Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, Crawford AH, Friedman JM, Little D, Peltonen J, Carey JC, Feldman D, Yu X, Armstrong L, Birch P, Kendler DL, Mundlos S, Yang F-C, Agiostratidou G, Hunter-Schaedle K, Stevenson DA. 2009. Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. Am J Med Genet Part A 149A:2327-2338.
7. Evans DG. 2009. Neurofibromatosis type 2 (NF2): Aclinical and molecular review. Orphanet J Rare Dis 4:16.
8. Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein P, Slattery W III, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M. 2009. Consensus recommendations to accelerate clinical trials for neuro-fibromatosis type 2. Clin Cancer Res 15:5032-5039.
9. Flaiz C, Ammoun S, Biebl A, Hanemann CO. 2009a. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain Pathol 19:27-38.
10. Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO. 2009b. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol 218:137-144.
11. Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG. 2008. Molecular characterisation ofSMARCB1and NF2 in familial and sporadic schwannomatosis. J Med Genet 45:332-339.
12. Hamaratoglu F, WilleckeM,Kango-SinghM,Nolo R,HyunE,Tao C, Jafar-Nejad H, Halder G. 2006. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8:27-36.
13. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag E, Baas F, Wesseling P. 2007. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80:805-810.
14. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever P, Lim M, Conway SJ, Parada LF, Zhu Y, Morrison SJ. 2008. The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 13:129-140.
15. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M. 2002. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060-1065.
16. Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, Mason RP, Lee EY, WuH, Parada LF. 2008. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68:3286-3294.
17. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. 2005. Diagnostic criteria for schwannomatosis. Neurology 64:1838-1845.
18. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N. 2009. Integrative genomic analyses show altered Schwann cell development in Neurofibromatosis tumors and implicate SOX9 as an addicting oncogene. EMBO Mol Med 1:236-248.
19. O'Neill E, Rushworth L, Baccarini M, Kolch W. 2004. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306:2267-2270.
20. Patil S, Perry A, MacCollin M, Dong S, Betebsky RA, Yeh TH, Gutmann DH, Stemmer-Rachamimov AO. 2008. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol 18:517-519.
21. Plotkin SR, Stemmer-Rachamimov AO, BarkerFGII, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. 2009. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358-367.
22. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. 2008. Efficient tumour formation by single human melanoma cells. Nature 456:593-598.
23. Revencu N, Boon LM, Mulliken JB, Enjolras O, Cordisco MR, Burrows PE, Clapuyt P, Hammer F, Dubois J, Baselga E, Brancati F, Carder R, Quintal JM, Dallapiccola P, Fischer G, Frieden IJ, Garzon M, Harper J, Johnson-Patel J, Labreze C, Martorell L, Paltiel HJ, Pohl A, Prendiville J, Quere I, Siegel DH, Valente EM, Van Haagen A, Van Hest L, Vaux KK, Vicente A, Weibel L, Chitayat D, Vikkula M. 2008. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 29:959-965.
24. Spurlock G, Bennett E, Chuzhanova N,Thomas N, Jim HP, Side L, Davies S, Haan E, Kerr B, Huson SM, Upadhyaya M. 2009. SPRED1 mutations (Legius syndrome): Another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. J Med Genet 46:431-437.
25. Tidyman WE, Rauen KA. 2009. The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19:230-236.
26. Williams JP, WuJ, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N. 2008. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofi-broma tumorigenic potential. Cell Stem Cell 3:658-669.
27. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. 2009. Neurofibromatosis type 1 revisited. Pediatrics 123:124-133.
28. ZhuY, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119-130.
29. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D. 2009. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 249:1014-1022.